BusinessNews Pulse
Aytu outlines $49M-$54M FY27 operating expense plan as it targets 66%-67% gross margin in Q4 FY27 (NASDAQ:AYTU)
Aytu BioPharma (AYTU) Q4 FY2026 earnings call recap: EXXUA script growth, revenue beat, positive EBITDA, FY2027 margin/OpEx outlook and risks—read now…
Read the full pulseContinue in Briflio to read, react, comment, and share.